Medicinal chemistry

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Flow Cytometry #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Oncology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Opportunities For Phenotypic Screening In Drug Discovery

Opportunities For Phenotypic Screening In Drug Discovery By David C. Swinney Renewed awareness of the value of phenotypic screening to drug discovery creates many new opportunities to increase drug discovery success and productivity. These opportunities include identification of translational phenotypic biomarkers, development of new assays that translate to human disease… Read More

#Archive

#Academic #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Medicinal chemistry #Molecular medicine #Oncology #Orphan drugs #Pathology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Reconfiguring Drug Discovery Through Innovative Partnerships

Reconfiguring Drug Discovery Through Innovative Partnerships By Dr Robert Grundy, Iain James, Chas Bountra and Timothy Harrison Attrition rates in drug discovery and development remain stubbornly high, despite large investments by the pharmaceutical industry. The cost of developing a new drug has been estimated at between $1.3 billion and upwards… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #Pharmacology #Regulatory #RNA #Screening #System biology #Systems biology #Translational #Translational chemistry #Urinary

Targeted Chemical Libraries: The keys to unlock the ubiquitin system

Targeted Chemical Libraries: The keys to unlock the ubiquitin system By Dr Jason Brown and Dr J. Mark Treherne Is novel chemistry the final frontier for ubiquitin system drug discovery?     Although the widespread use of target-focused libraries has led to the rapid expansion of novel chemistry as research… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Chemical engineering #Chemistry #Drug discovery #Drug targets #Enabling technologies #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #Organic chemistry #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Target validation #Therapeutics

Library Logistics: Managing Comprehensive Compound Collections

Library Logistics: Managing Comprehensive Compound Collections By Dr Jorg Kroll and David Booth Compound management may seem straightforward but in reality, as the number of new compounds increases dramatically year-on-year, the management of large collections has become increasingly challenging. As highthroughput technologies have become the norm, Bayer HealthCare, a global… Read More

#Archive

#ADME / Tox #Analysis #Automation / robotics #Business #Chemistry #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Drug targets #High Content Screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #PCR #Pharmokinetics #RNA #System biology

Rules For Drug Discovery: Can simple property criteria help you to find a drug?

Rules For Drug Discovery: Can simple property criteria help you to find a drug? By Dr Matthew Segall The years since the publication of Lipinski’s Rule of Five (Ro5) (1) in 1997 have seen the growth of a minor industry, dedicated to generating new ‘rules’ for drug discovery. Fuelled by… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics

Building New Models of Drug Discovery in Europe – The Innovative Medicines Initiative

Building New Models of Drug Discovery in Europe - The Innovative Medicines Initiative By Dr Angela Wittelsberger, Dr Hugh Laverty and Dr Michel Goldman The discovery and development of a new medicine is time-consuming, risky and expensive. It often takes 10-15 years and an investment of on average >$1 billion… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #Immunology #Lead discovery #Medicinal chemistry #Patent Law #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Target validation #Toxicology

Collaboration For Innovation Is The New Mantra For The Pharmaceutical Industry

Collaboration For Innovation Is The New Mantra For The Pharmaceutical Industry By Professor Jackie Hunter In order to maintain a flow of innovative medicines there is a growing realisation that companies cannot allow the status quo to remain as it is and the need to identify sources of appropriate knowledge… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Immunology #Lead discovery #Medicinal chemistry #Molecular medicine #Oncology #Pathology #PCR #Preclinical #Regenerative Medicine #RNA #Stem cells #Therapeutics #Translational #Translational chemistry

More Than Genes and Cells: Drug Discovery in the Extracellular Matrix (ECM)

More Than Genes and Cells: Drug Discovery in the Extracellular Matrix (ECM) By Dr William Bains Drug discovery in the last few decades has focused on the cellular and genetic mechanisms of disease. This has been very successful in cancer, which is a disease of somatic genetics, and moderately successful… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Flow Cytometry #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Oncology #Pathology #Pharmacology #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

Large-Scale Expansion of Stem Cells For Therapy and Screening

Large-Scale Expansion of Stem Cells For Therapy and Screening By Dr Y. John Shyu, Dr Katherine E. Strathearn and Dr Richard M. Eglen Recently, pre-clinical and clinical studies of stem cells in regenerative medicine have demonstrated great promise as treatments for various diseases. Their ability to self-renew and differentiate makes… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Chemistry #Clinical trials #Drug development #Drug discovery #High Content Screening #Imaging #Lead discovery #Lead optimisation #Medicinal chemistry #Pathology #Pharmacology #Preclinical #Regulatory #RNA #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Partnering with the right CRO is a winning strategy for companies big and small

Partnering with the right CRO is a winning strategy for companies big and small By Dr Davide Molho The Bio-Pharma business model is undergoing radical changes. Over the last two decades, we have seen the biopharmaceutical industry gradually become more willing to look externally and embrace the concept of outsourcing… Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Oncology #Pharmacology #Pharmokinetics #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Translational #Translational chemistry

Outsourced Kinase Profiling Services: Adding Value To In-House Kinase Programmes

Outsourced Kinase Profiling Services: Adding Value To In-House Kinase Programmes Dr John Comley Biochemical kinase profiling using a large panel of kinases with a broad coverage of the human kinome has become the de facto norm within the Pharma industry. The importance of this activity is demonstrated by the large… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Isotope labelling #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Oncology #Organic chemistry #PCR #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics

Multi-Parameter Flow Cytometry Technology Advances for Rare Cell Analysis and Sorting

Multi-Parameter Flow Cytometry Technology Advances for Rare Cell Analysis and Sorting By David Gebhard and Dr Diether Recktenwald The study of rare cell populations is important to advance medical diagnostics and therapeutics. For many clinical studies, rare cell counts promise to provide valuable alternate end points; examples are circulating tumour… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #Oncology #Orphan drugs #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Therapeutics

Challenges and Opportunities In The Treatment Of Rare Diseases

There are approximately 7,000 rare diseases, which from a regulatory perspective are defined as those diseases where there are less than 200,000 patients in the US or that affect no more than five in 10,000 of the general population in the EU. Such diseases usually have a genetic basis, often… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Business #Chemistry #Clinical trials #Drug development #Drug discovery #Isotope labelling #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #Organic chemistry #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Target validation

Carbon-14 Labelled API Manufacturing

Carbon-14 Labelled API Manufacturing By Dr Sean L. Kitson and Dr David Speed Carbon-14 labelled API and IMP requirements for Phase 0/I to Phase III mass balance and micro-dosing clinical trials can be met by contract manufacturing in compliance with MHRA and FDA Phase I cGMP guidelines. The short supply… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biochemistry #Business #Cellular & Molecular biology #Chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #PCR #RNA #Screening

Fragment Library Design – The Evolution Of Fragment Based Lead Discovery

Fragment Library Design - The Evolution Of Fragment Based Lead Discovery By Dr Edward Zartler, Dr Chris Swain and Simon Pearce With the growing need to streamline the drug discovery process, screening against fragment libraries rather than drug-like molecules has become increasingly adopted as an integral part of many drug… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Cellular assays #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genomics #High Content Screening #Imaging #Immunology #Lead discovery #Medicinal chemistry #Oncology #Pharmacogenomics #Pharmacology #Regenerative Medicine #Regulatory #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

The Challenges Of The Changing Drug Discovery Model

The Challenges Of The Changing Drug Discovery Model By Dr Mark Downs and Dr Tom Blackburn The drug development industry is restructuring worldwide. This brings different ways of working and new challenges. As the industry moves away from internally focused research to an external model, project management and communication of… Read More

#Archive